BioCryst Pharmaceuticals Inc. (BCRX)
NASDAQ · Healthcare
BioCryst Pharmaceuticals Inc. Long Term Debt 2009–2025
BioCryst Pharmaceuticals Inc. annual long term debt history from 2016 to 2024. Long term debt refers to financial obligations that are due more than one year in the future.
- BioCryst Pharmaceuticals Inc. long term debt as of December 31, 2024: 314.9M, a 3.84% increase year-over-year.
- BioCryst Pharmaceuticals Inc. long term debt for 2024 were 314.9M, a 3.84% increase from 2023.
- BioCryst Pharmaceuticals Inc. long term debt for 2023 were 303.2M, a 30.92% increase from 2022.
- BioCryst Pharmaceuticals Inc. long term debt for 2022 were 231.6M, a 22.31% decrease from 2021.
- BioCryst Pharmaceuticals Inc. long term debt for 2021 were 298.1M.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| BioCryst Pharmaceuticals Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2024 | $315 |
| 2023 | $303 |
| 2022 | $232 |
| 2021 | $298 |
| 2020 | $123 |
| 2019 | $50 |
| 2018 | $30 |
| 2017 | $23 |
| 2016 | $23 |
BioCryst Pharmaceuticals Inc. Long Term Debt — FAQ
BioCryst Pharmaceuticals Inc. (BCRX) long term debt over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BCRX's long term debt history?
The chart and table above show BioCryst Pharmaceuticals Inc.'s long term debt by year and by quarter, including the growth rate.